Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00443287 | Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease | PHASE2 | COMPLETED | 553 | — | — | Feb 1, 2007 | Oct 1, 2008 | May 17, 2018 | 7 | United States, Austria +5 |
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | - |
| 2 | EXPERIMENTAL | dose level 1 |
| 3 | EXPERIMENTAL | dose level 2 |
| 4 | EXPERIMENTAL | dose level 3 |
| 5 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ataciguat (HMR1766) | DRUG | oral administration |
| placebo | DRUG | oral administration |
| cilostazol | DRUG | oral administration |
Inclusion Criteria: * Patient with stable symptoms of intermittent claudication of the lower extremities, secondary to chronic occlusive arterial disease from atherosclerosis etiology (symptoms present for 6 months or longer and not significantly changed within the past 3 months) * Initial claudica...